On the morning of June 3, the Executive Roundtable on Code Implementation and the China Consensus Framework (hereinafter referred to as “the roundtable”), co-hosted by China Pharmaceutical Innovation and Research Development Association (PhIRDA), China Pharmaceutical Industry Association (CPIA), China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) and the R&D-based Pharmaceutical Association Committee (RDPAC), was successfully held in Beijing. Over 60 domestic and foreign experts and senior executives from pharmaceutical associations and compliance departments of enterprises attended the roundtable.

Dr. Song Ruilin, Executive President of PhIRDA, attended the roundtable and made the opening speech, and pointed out that medical and pharmaceutical products were branded with fairly high commodity and sociality, bearing the relevant social responsibility when chasing reasonable prices and values. Since 2005, the reform of drug review and approval system, China has been gradually integrated into the global standard of drug quality control. China's joining in ICH marked the full integration with the international market in the whole industry chain of drug R&D. At present, facing the China-US trade dispute, it is more important take thecode of ethicsfrom the perspective from the SMEs to the whole nation, to strengthen the cooperation and exchange of the biopharmaceutical industry between countries, and to focus more from a global perspective, so as to lead the industry and guide the development.

Dr. Song Ruilin, Executive President of PhIRDA, made the opening speech

Ms. Feng Lan, Secretary-General of PhIRDA, introduced the progress and the implementation ofPhIRDA Code of Ethics. PhIRDA attaches great importance to the development of ethical codes in the Chinese pharmaceutical industry in the new era, and promotes the implementation of ethical codes in the pharmaceutical industry by participating in activities organized by APEC and IFPMA. PhIRDA signed the “Consensus Framework for the Ethical Collaboration in the Pharmaceutical and Medical Device Sectors” in July, 2018, and approvedPhIRDA Code of Ethicson the Fifth Meeting of the 10thPhIRDA General Assembly in September, 2018. As the first domestic association representing pharmaceutical industry in China, PhIRDA established and implemented relevant rules, so as to improve the ability to comply with the code of ethics and to control risks, and to build a better environment for the innovative pharmaceutical industry in China. Since the publication and implementation ofPhIRDACode of Ethics, no complaints against PhIRDA’s member have been reported, and all members have successively established and improved the internal ethical compliance system by relevant ethical standards. PhIRDA will continue to cooperate closely with APEC and IFPMA on the construction of the ethical code system, including improvingPhIRDACode of Ethics, providing more training on relevant laws and regulations, and working with all parties to promote the construction of the ethical code system in the pharmaceutical industry according to China's characteristics.

Ms. Feng Lan, Secretary-General of PhIRDA, introduced the progress and implementation ofPhIRDA Code of Ethics

Mr. Pan Guangcheng, Executive Chairman of CPIA, Mr. Zhou Hui, President of CCCMHPIE, Ms. Kang Wei, Managing Director of RDPAC, Mr. Zhang Shun, Deputy Director of Department of Legal Affairs of CCPIT, Ms. Melissa Stapleton Barnes, Chair of Ethics & Business Integrity Committee of IFPMA, Ms. Sofie Melis, Head of Ethics and Compliance of IFPMA, and Mr. Andrew Blasi, Director of C&M International & Technical Secretariat of Business Ethics for APEC SMEs Initiative participated in this roundtable, making a heated discussion on issues including the implementation of thecode of ethicsin China, the international leadership of Framework Consensus and so forth.

Centering on the principle of “innovation, industrialization and internationalization”, PhIRDA has always been committed to the development of China's pharmaceutical innovation industry, and the implementation of thecode of ethicsand consensus framework in the pharmaceutical industry, so as to integrate the compliance level of China's pharmaceutical industry with international standards.

The roundtable is a great platform for the Chinese and foreign experts and representatives in the field of pharmaceutical enterprises’ ethics compliance to make in-depth exchanges and cooperation, laying a solid foundation for the integration with the advanced international standard of ethical compliance. Ms. Lu Xiaoti, Deputy Secretary-General of PhIRDA, Ms. Ruan Xinxin, Deputy Director of International Affairs and Mr. Li Gen, Project Assistant attended the meeting.

Representatives of Host Organizations

Plenary Meeting